ATAI Life Sciences NV (ATAI) Actualités

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

atai Life Sciences Announces Pricing of Public Offering of Common Shares

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...

Form 424B5 - Prospectus [Rule 424(b)(5)]

atai Life Sciences Announces Proposed Public Offering of Common Shares

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or...

atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01...